SkinCeuticals Silymarin CF Vitamin C Serum — Oil Free Antioxidant Protection for Clear, Radiant, Blemish Prone Skin

Product Overview

SkinCeuticals Silymarin CF is the oily-skin counterpart to C E Ferulic, engineered to address the specific oxidative and inflammatory burden of seborrheic and acne-prone skin phenotypes. Silymarin, the principal flavonolignan complex extracted from Silybum marianum (milk thistle), provides potent antioxidant activity alongside documented sebostatic and anti-inflammatory properties. Unlike C E Ferulic, which pairs L-ascorbic acid with alpha tocopherol (vitamin E) — itself a potential comedogen in oily skin — Silymarin CF substitutes vitamin E with silymarin and adds 0.5% salicylic acid, a lipid-soluble beta-hydroxy acid that penetrates the pilosebaceous unit to exert comedolytic effects at concentrations above 0.1%. The formula is classified as an oil-free, lightweight serum and is compatible with acne management protocols.

The antioxidant framework functions as follows: L-ascorbic acid (15%) provides primary radical scavenging and collagen synthesis support via prolyl and lysyl hydroxylase enzyme cofactor activity; ferulic acid (0.5%) stabilises both L-ascorbic acid and silymarin against photodegradation while contributing independent phenolic antioxidant activity — achieving greater than 90% stability for L-ascorbic acid in formulation; silymarin (0.5%) reduces sebum oxidation and suppresses transcription factor NF-κB, thereby downregulating downstream pro-inflammatory mediators including COX-2, lipoxygenase (LOX), inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-1, mechanisms relevant to inflammatory acne pathogenesis. In peer-reviewed clinical study, a silymarin-containing antioxidant serum achieved statistically significant reductions in inflammatory and non-inflammatory acne lesion counts at 12 weeks compared to vehicle control.

Specifications

Key Applications

• Oily and seborrheic skin antioxidant maintenance: Daily topical antioxidant protection for patients with chronic seborrhoea, providing UV and pollution defence without occlusive emollients or comedogenic excipients.
• Comedonal and inflammatory acne adjunct: Salicylic acid at 0.5% penetrates pilosebaceous units and promotes individual corneocyte desquamation, reducing open comedone burden (11% greater reduction vs. vehicle) and inflammatory lesion count (25% greater reduction vs. vehicle at 12 weeks); used alongside topical retinoids or benzoyl peroxide under dermatologist supervision.
• Post-acne hyperpigmentation management: L-ascorbic acid inhibits tyrosinase, reducing melanin synthesis at post-inflammatory hyperpigmentation sites; used adjunctively with niacinamide or prescription hydroquinone regimens.
• Pre- and post-procedure antioxidant support for acne-prone patients: Applied before and after laser, light-based, and chemical peel procedures targeting acne or oily skin to reduce procedural oxidative stress and support wound healing without exacerbating comedonal occlusion.
• Photoprotection augmentation in high-UV environments: Ferulic acid stabilisation doubles the photoprotective efficacy of the vitamin C and silymarin combination; applied before SPF 30+ for comprehensive oxidative and UV defence in Singapore's high-irradiance equatorial climate.

Frequently Asked Questions

Q: How does Silymarin CF differ from C E Ferulic, and how should a clinician select between them?
A: Silymarin CF targets oily and acne-prone skin phenotypes: it substitutes alpha tocopherol (vitamin E) — which may be comedogenic at higher concentrations — with silymarin and adds 0.5% salicylic acid for pilosebaceous penetration and comedolysis. C E Ferulic (15% L-ascorbic acid, 1% alpha tocopherol, 0.5% ferulic acid) is formulated for normal, dry, and sensitive skin, with a broader photoprotection data set from Duke University. Clinicians should select Silymarin CF for patients with active seborrhoea, acne, enlarged pores, or vitamin E intolerance, and C E Ferulic for photoaged, normal-to-dry skin.

Q: Is salicylic acid at 0.5% safe for daily morning use alongside prescription acne treatments?
A: At 0.5%, salicylic acid exerts mild comedolytic activity with a low irritation profile suitable for daily use. However, concurrent use with topical retinoids (tretinoin, adapalene), benzoyl peroxide, or alpha-hydroxy acid (AHA) exfoliants may cumulatively increase barrier disruption and erythema, particularly in humid climates such as Singapore. Clinicians and aesthetic practitioners should advise patients to introduce Silymarin CF gradually and monitor for signs of barrier compromise before layering with other active ingredients.

Q: Is Silymarin CF compatible with acne prescription regimens including oral isotretinoin?
A: During oral isotretinoin therapy, the sebaceous glands are pharmacologically suppressed, significantly reducing oiliness. In this context, Silymarin CF (formulated for oily skin) may cause relative dryness; patients on isotretinoin may be better served by C E Ferulic or a less active topical antioxidant. Post-isotretinoin, as sebaceous activity normalises, Silymarin CF may be re-introduced. All decisions should be guided by the prescribing dermatologist's protocol, as isotretinoin-associated mucocutaneous fragility can alter topical tolerability.

Q: How is this product regulated and authenticated in Singapore?
A: SkinCeuticals Silymarin CF is classified as a cosmetic product under the Singapore Health Products Act (Cap. 122D) and the Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007, administered by the Health Sciences Authority (HSA). EMIS sources product through authorised distributor channels; authentication via lot number traceability is available on request. Clinics and aesthetic practices should retain purchase documentation and be aware that HSA may request cosmetic notification records during market surveillance activities.

Q: How should the product be stored and what are the signs of degradation?
A: Store below 25°C, away from direct sunlight, heat, and air exposure. L-ascorbic acid undergoes progressive oxidation; colour change from pale straw-yellow to orange or brown indicates significant oxidative degradation. A brown formulation delivers substantially reduced antioxidant activity and should be discarded. Ferulic acid at 0.5% extends formulation stability; however, storage compliance remains critical. Opened product should ideally be used within 3–6 months.

Available in Singapore from EMIS (Essential Medical International Supplies Pte Ltd). For professional procurement or clinic stock enquiries, contact our B2B team at emis.asia.